Second-line monotherapy with a PD-1/CTLA-4 inhibitor effectively treated multiple brain and lung metastases of cervical cancer: a case report

Front Immunol. 2024 Oct 14:15:1434697. doi: 10.3389/fimmu.2024.1434697. eCollection 2024.

Abstract

Background: Brain metastasis (BM) from cervical cancer (CC) is extremely rare. The prognosis of BM is poor. To our knowledge, no satisfactory therapeutic and standard effective treatments have been established. Immune checkpoint inhibitors (ICIs) treatment is emerging as a promising treatment in recurrence and metastasis(B/M) cervical cancer in recent years.

Case: We present a 50-year-old patient with CC who developed multiple metastasis (lung, brain and skin) 2 years after postoperative chemoradiotherapy. She received palliative therapy included chemotherapy, resection and stereotactic radiosurgery of BM with poor response. Then, the patient received second-line palliative monotherapy with a PD-1/CTLA-4 inhibitor(cadonilimab) and achieved clinical very good partial response (VGPR), a progression-free survival (PFS) of 14 months and overall survival of more than 18 months since BM.

Conclusion: We report a case of cervical cancer with multiple metastasis receiving cadonilimab and achieved considerable response and survival benefit.

Keywords: PD-1/CTLA-4 inhibitor; brain metastasis; case report; cervical cancer; immunotherapy.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / secondary
  • CTLA-4 Antigen* / antagonists & inhibitors
  • Female
  • Humans
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / secondary
  • Middle Aged
  • Programmed Cell Death 1 Receptor* / antagonists & inhibitors
  • Uterine Cervical Neoplasms* / drug therapy
  • Uterine Cervical Neoplasms* / pathology

Substances

  • Immune Checkpoint Inhibitors
  • Programmed Cell Death 1 Receptor
  • CTLA-4 Antigen
  • PDCD1 protein, human
  • Antibodies, Monoclonal, Humanized
  • CTLA4 protein, human

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by Medical Science and Technology Foundation of Zhejiang Province (2021KY54, 2020KY020 and 2023KY013).(Every funding was received by government grants, no entanglements with individuals or corporations).